Cost of cystic fibrosis drug, others threatens system, doctors say

At a cost of more than $300,000 a year, the new cystic fibrosis drug, Kalydeco, is one of the most expensive pills in American medicine. In early October, three doctors who treat cystic fibrosis patients said that kind of extremely high pricing for new drugs that treat rare conditions threatens the U.S. health care system and can’t be sustained.

Continue reading Cost of cystic fibrosis drug, others threatens system, doctors say

KaloBios Says Cystic Fibrosis-Related Treatment Gains Orphan-Drug Status

KaloBios Pharmaceuticals Inc. (KBIO) said the U.S. Food and Drug Administration granted orphan-drug designation for its treatment for cystic fibrosis patients with Pseudomonas aeruginosa. Continue reading KaloBios Says Cystic Fibrosis-Related Treatment Gains Orphan-Drug Status

Teva announces FDA approval of generic TOBI in the United States

JERUSALEM–(BUSINESS WIRE)–Oct. 14, 2013– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI® (Tobramycin Inhalation Solution Continue reading Teva announces FDA approval of generic TOBI in the United States

Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients

Pharmaceutical discovery and development company Celtaxsys, Inc. today announced it is now enrolling patients for its first trial of CTX-4430 oral treatment for lung disease in Cystic Fibrosis (CF) patients. In this study, the safety and Continue reading Celtaxsys Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients

Why AbbVie’s Global Alliance With Galapagos Is Good News for Investors

Since becoming an independent company late last year, AbbVie has been making significant progress. AbbVie shares have been among the best performers in the health care sector this year, gaining nearly 31% year-to-date. The gains have come Continue reading Why AbbVie’s Global Alliance With Galapagos Is Good News for Investors

If Chosen Wisely, Existing Drugs Fight Resistant Bugs

Science/AAAS | News
Fatal weakness. Pathogens such as methicillin-resistant Staphylococcus aureus (above) develop vulnerabilities as they evolve resistance to antibiotics. Choosing antibiotics that exploit these weaknesses can thwart resistant bacteria. Continue reading If Chosen Wisely, Existing Drugs Fight Resistant Bugs

Celtaxsys completes Phase I trial of cystic fibrosis drug

US-based clinical stage drug discovery and development firm Celtaxsys has completed Phase I clinical trial of its drug CTX-4430 to treat patients with cystic fibrosis (CF) lung disease.

Celtaxsys Aus, the company’s Australian subsidiary, has carried out the first of two clinical trials in Continue reading Celtaxsys completes Phase I trial of cystic fibrosis drug

Cornerstone Therapeutics Initiates PERTZYE® (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

CARY, N.C., July 29, 2013 – Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today it is now actively marketing PERTZYE® (pancrelipase) in the U.S. for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis. PERTZYE is the only U.S. Food and Drug Administration (FDA) approved pancreatic enzyme replacement therapy (PERT) containing Continue reading Cornerstone Therapeutics Initiates PERTZYE® (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections; Bauer KA, West JE, O’Brien JM, Goff DA; Antimicrobial Agents & Chemotherapy (Apr 2013)

In an era of escalating resistance and lack of new antimicrobial discovery, stewardship programs must utilize knowledge of pharmacodynamics to achieve maximal exposure in the treatment of Pseudomonas aeruginosa infections. We evaluated the clinical and Continue reading Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections; Bauer KA, West JE, O’Brien JM, Goff DA; Antimicrobial Agents & Chemotherapy (Apr 2013)